Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00530595
Recruitment Status : Completed
First Posted : September 17, 2007
Last Update Posted : September 17, 2007
Information provided by:
Saitama Medical University

Brief Summary:
Cardiovascular disease is a leading cause of mortality in patients on hemodialysis therapy (HD), accounting for 30 to 50% of all death. Although angiotensin receptor blockers (ARBs) are effective for patients with diabetes and chronic kidney disease in reducing or preventing cardiovascular diseases, there has been no decisive study that demonstrated treatment with ARBs is effective in patients on HD.

Condition or disease Intervention/treatment Phase
Cardiovascular Disease Drug: candesartan or valsartan or losartan Not Applicable

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 30 to 80 years of age
  • Receiving hemodialysis at least 12 months and less than 5 years
  • Pre-dialysis systolic blood pressure was more than 160 mmHg, or more than 150 mmHg if the patients received antihypertensive agents.

Exclusion Criteria:

  • Use of angiotensin receptor blocker or angiotensin converting enzyme inhibitor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00530595

Sponsors and Collaborators
Saitama Medical University
Study Director: Hiromichi Suzuki, MD, PhD Department of Nephrology, Saitama Medical University

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00530595     History of Changes
Other Study ID Numbers: S-01
First Posted: September 17, 2007    Key Record Dates
Last Update Posted: September 17, 2007
Last Verified: September 2007

Keywords provided by Saitama Medical University:

Additional relevant MeSH terms:
Cardiovascular Diseases
Angiotensin Receptor Antagonists
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Molecular Mechanisms of Pharmacological Action
Anti-Arrhythmia Agents